This was the stock's second consecutive day of losses.

Corbus Pharmaceuticals (CRBP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ...

The stock's fall snapped a two-day winning streak.

Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Oppenheimer analyst Jeff Jones reiterated a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based company said it had a loss of 78 cents per share. The ...

Since CEO Elon Musk went to Washington, Tesla's stock has tumbled nearly 48%. Since Elon Musk went to Washington, D.C., to slash the government alongside President Donald Trump, the stock of his ...

With rapid growth and the stock trading for about 21 times forward earnings, now could be a great opportunity. PayPal fell sharply after its latest earnings report disappointed growth-seeking ...